Top in cardiology: Cannabis and CVD risk, survival benefit of Vyndamax

In last week’s top story in cardiology, a cross-sectional analysis found that cannabis use was significantly associated with increased odds of having a high atherosclerotic CVD risk.

Moreover, the researchers reported observing a dose-response relation between increased cannabis use and a higher risk of atherosclerotic CVD (ASCVD).

Another top story was about new data on Vyndamax (tafamidis, Pfizer), which conferred a 5-year survival benefit in patients with transthyretin amyloid cardiomyopathy compared with those who received placebo.

Read these and more top stories in cardiology below:

CVD risk factors associated with cannabis use

Elevated ASCVD risk was linked to cannabis use in a study published in the American Journal of Cardiology. Read more.

Tafamidis confers 5-year survival benefit in transthyretin amyloid cardiomyopathy

Compared with placebo, tafamidis was linked to improved long-term survival in patients with transthyretin amyloid cardiomyopathy, according to new data from the ATTR-ACT trial. Read more.

Catheter ablation outcomes in patients with AF vary by age: CABANA

Compared with drug therapy, there was age-based variation in catheter ablation clinical outcomes among patients with atrial fibrillation, with the largest benefits observed in younger patients, according to new data from the CABANA trial. Read more.

The Take Home: AHA Scientific Sessions

The American Heart Association Scientific Sessions were held virtually Nov. 13 to 15. The event included numerous presentations of new data in cardiology. Read more.

Smartphone voice analysis may identify pulmonary congestion in acute decompensated HF

Automated speech analysis using a smartphone app may be able to detect pulmonary fluid overload in adult patients hospitalized with acute decompensated heart failure, according to research published in JACC: Heart Failure. Read more.